Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

– Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Collegium Estimates Q2'24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024 Financial Guidance for the Current Business – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive ...